Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06127108 · ClinicalTrials.gov registry record · NA

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel

A NA study of COVID-19 and Influenza a, sponsored by Abbott Rapid Dx.

Completed
Registry status
NA
Development phase
447
Enrollment target
1
Study location

NCT06127108: Completed NA study of COVID-19 and Influenza a, sponsored by Abbott Rapid Dx.

NCT06127108 is a NA study of COVID-19 and Influenza a that has completed, run by Abbott Rapid Dx. The registered enrollment target is 447 participants, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06127108, a NA study of COVID-19 and Influenza a, has completed, sponsored by Abbott Rapid Dx.

COMPLETED
Registry status
NA
Development phase
447 participants
Enrollment target
1
Study location

Study Summary

The study is designed as a prospective, multicentric, clinical study to investigate the positive percent agreement (PPA) and negative percent agreement (NPA) of the Panbio™ COVID-19/Flu A\&B Panel using anterior nasal swab specimens tested directly, relative to the comparator methods, Roche cobas® SARS-CoV-2 (K231306) and Quidel Lyra® Influenza A+B Assay(K230236) (RT-PCR) in symptomatic patients suspected of respiratory viral infection by a healthcare provider.

Primary Outcome

1\. Primary Outcome: The primary objective of this study is to demonstrate the positive percent agreement (PPA) and negative percent agreement (NPA) of the Panbio™ COVID-19/Flu A\&B Panel using anterior nasal swab specimens tested directly, relative to the comparator methods, the Roche cobas® SARS-CoV-2 (K231306) and Quidel Lyra® Influenza A+B Assay (K230236) (RT-PCR) in symptomatic patients suspected of respiratory viral infection by a healthcare provider. Samples may also be tested for viral c

Interventions

  • DIAGNOSTIC_TEST Panbio™

Study Locations (1)

Virginia

  • Advanced Pediatrics - Vienna

Trial Details

FieldValue
Enrollment Target 447 participants
Start Date 2023-11-14
Est. Completion 2024-02-02
Phase NA
Abbott Rapid Dx

5 total trials

What the finished NCT06127108 record still lists

NCT06127108 is an interventional study that assigns participants to a tested intervention. The registered 447 participants enrollment target is mid-sized for trials with a published cap, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Panbio™ is the first listed.

NCT06127108 reports a single indexed study location in Virginia.

Frequently Asked Questions

What is clinical trial NCT06127108 about?

NCT06127108 is a clinical study titled "Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel". The study is designed as a prospective, multicentric, clinical study to investigate the positive percent agreement (PPA) and negative percent agreement (NPA) of the Panbio™ COVID-19/Flu A\&B Panel using anterior nasal swab specimens tested directly, relative to the comparator methods, Roche cobas® S...

What is the current status of trial NCT06127108?

This trial is currently completed. It is a NA study. The enrollment target is 447 participants. The study started on 2023-11-14. Estimated completion is 2024-02-02.

What conditions does trial NCT06127108 study?

This clinical trial studies the following conditions: COVID-19, Influenza a, Influenza B.

What interventions are being tested in trial NCT06127108?

The interventions under investigation include: Panbio™ (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06127108?

This trial is sponsored by Abbott Rapid Dx, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06127108 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06127108's enrollment target sits among peer trials

447 119th of 298 higher than 180 of 298 other COVID-19 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04065399 · 447 participants · Phase 1

    A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • NCT06702449 · 448 participants · Phase 1

    A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

  • NCT07125053 · 448 participants · NA

    COPD Resources, Education, and Activity Designed for You Study

  • NCT01280994 · 445 participants · Phase 2

    Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06127108, the US trial registry maintained by the National Library of Medicine. NCT06127108 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.